Guardant Health
Guardant Health Lays off 7 Percent of Workforce
In a statement, Guardant Health cited the need to balance innovation with "financial discipline and focused execution" in the current economic environment.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, QuidelOrtho, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.
Guardant Health Preliminary Q4 Revenues Grow 15 Percent to 17 Percent
Guardant reported preliminary fourth quarter revenues of between $124 million and $127 million, topping analysts' average estimate of $122.7 million.
360Dx Top 30 Ends 2022 With 2 Percent Dip in December
Of the 30 companies in the index, nine saw their stock prices rise, while 21 firms' share prices decreased.